These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. Marcucci KT; Jadlowsky JK; Hwang WT; Suhoski-Davis M; Gonzalez VE; Kulikovskaya I; Gupta M; Lacey SF; Plesa G; Chew A; Melenhorst JJ; Levine BL; June CH Mol Ther; 2018 Jan; 26(1):269-279. PubMed ID: 29203150 [TBL] [Abstract][Full Text] [Related]
6. Development of an equine-tropic replication-competent lentivirus assay for equine infectious anemia virus-based lentiviral vectors. Farley DC; Bannister R; Leroux-Carlucci MA; Evans NE; Miskin JE; Mitrophanous KA Hum Gene Ther Methods; 2012 Oct; 23(5):309-23. PubMed ID: 23121195 [TBL] [Abstract][Full Text] [Related]
7. "RCL-Pooling Assay": A Simplified Method for the Detection of Replication-Competent Lentiviruses in Vector Batches Using Sequential Pooling. Corre G; Dessainte M; Marteau JB; Dalle B; Fenard D; Galy A Hum Gene Ther; 2016 Feb; 27(2):202-10. PubMed ID: 26886834 [TBL] [Abstract][Full Text] [Related]
8. Detection of replication competent retrovirus and lentivirus. Sastry L; Cornetta K Methods Mol Biol; 2009; 506():243-63. PubMed ID: 19110631 [TBL] [Abstract][Full Text] [Related]
9. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector. Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055 [TBL] [Abstract][Full Text] [Related]
10. Development of a sensitive assay for detection of replication-competent recombinant lentivirus in large-scale HIV-based vector preparations. Escarpe P; Zayek N; Chin P; Borellini F; Zufferey R; Veres G; Kiermer V Mol Ther; 2003 Aug; 8(2):332-41. PubMed ID: 12907156 [TBL] [Abstract][Full Text] [Related]
11. Patient monitoring and follow-up in lentiviral clinical trials. McGarrity GJ; Hoyah G; Winemiller A; Andre K; Stein D; Blick G; Greenberg RN; Kinder C; Zolopa A; Binder-Scholl G; Tebas P; June CH; Humeau LM; Rebello T J Gene Med; 2013 Feb; 15(2):78-82. PubMed ID: 23322669 [TBL] [Abstract][Full Text] [Related]
17. Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its replication. Klimatcheva E; Planelles V; Day SL; Fulreader F; Renda MJ; Rosenblatt J Mol Ther; 2001 Jun; 3(6):928-39. PubMed ID: 11407907 [TBL] [Abstract][Full Text] [Related]
18. Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Manilla P; Rebello T; Afable C; Lu X; Slepushkin V; Humeau LM; Schonely K; Ni Y; Binder GK; Levine BL; MacGregor RR; June CH; Dropulic B Hum Gene Ther; 2005 Jan; 16(1):17-25. PubMed ID: 15703485 [TBL] [Abstract][Full Text] [Related]
19. In vivo selection for human and murine hematopoietic cells transduced with a therapeutic MGMT lentiviral vector that inhibits HIV replication. Davis BM; Humeau L; Dropulic B Mol Ther; 2004 Feb; 9(2):160-72. PubMed ID: 14759800 [TBL] [Abstract][Full Text] [Related]
20. Development of a replication-competent lentivirus assay for dendritic cell-targeting lentiviral vectors. Farley DC; McCloskey L; Thorne BA; Tareen SU; Nicolai CJ; Campbell DJ; Bannister R; Stewart HJ; Pearson LJ; Moyer BJ; Robbins SH; Zielinski L; Kim T; Radcliffe PA; Mitrophanous KA; Gombotz WR; Miskin JE; Kelley-Clarke B Mol Ther Methods Clin Dev; 2015; 2():15017. PubMed ID: 26029728 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]